Antibiotic resistance is a moving target, and even the most successful drugs eventually lose their edge. Around the turn of ...

Antibiotics are a crucial tool in the fight against bacterial infections. But the World Health Organization has long warned that we are facing an antibiotic crisis. Bacteria can easily adapt, evolve, ...

de la Fuente-Nunez is a presidential associate professor at the University of Pennsylvania. Skinner is CEO of the AMR Action Fund. Of all the areas of drug development that artificial intelligence has ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Novartis is expanding India’s role in pharmaceutical R&D, clinical research and innovative medicines following its strategic ...

Scientists from the University of Tübingen and Monash University studied glycopeptide antibiotics, a key resource in countering drug-resistant pathogens, to uncover their evolutionary origins to gain ...

Although the past decade has been marked by lack of innovation in the field of antibiotics development, that trend is changing, according to data from Reportlinker. According to the data, 109 ...

Digital pathology and artificial intelligence are transforming the drug development landscape, accelerating the path to ...

Ultragenyx’s Rare Bootcamp gives families a roadmap to help drive research and develop new treatments for rare diseases.

From shrinking drug development timelines to scouting potential acquisitions, the recent run of first-quarter earnings results marked a shift for Big Pharma from AI hype to explaining how the ...